Chronic Obstructive Pulmonary Disease (COPD) Therapies
Chronic Obstructive Pulmonary (COPD) Disease Market

Chronic Obstructive Pulmonary Disease 


Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. In the United States, the term COPD includes two main conditions—emphysema and chronic bronchitis. In emphysema, the walls between many of the air sacs are damaged. As a result, the air sacs lose their shape and become floppy.


Chronic Obstructive Pulmonary Disease Epidemiology Segmentation in the 7MM 


  • Diagnosed Prevalent cases of COPD
  • Gender-specific Diagnosed Prevalent cases of COPD
  • Age-specific Diagnosed Prevalent cases of COPD
  • Diagnosed Prevalent Cases of COPD Based on Severity of Airflow
  • Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History COPD


Chronic Obstructive Pulmonary Disease Epidemiological Insights Observed in the 7MM (2020)


  • The total diagnosed prevalent population of Chronic Obstructive Pulmonary Disease in the 7MM was estimated to be 34.6 million.
  • The total diagnosed prevalent population of Chronic Obstructive Pulmonary Disease in the US was found to be 17.4 million.
  • The total Gender-specific cases of Chronic Obstructive Pulmonary Disease in the 7MM where males were found to be 6.5 million and the females were estimated to be 10.8 million in the year 2020.


Chronic Obstructive Pulmonary Disease Market Insight


The market size of Chronic Obstructive Pulmonary Disease in the 7MM was found to be USD 12,333 million in 2020.  


Chronic Obstructive Pulmonary Disease Market Drivers


  • Increasing prevalence of COPD
  • Emergence in the development of emerging therapies
  • Personalized treatments
  • Entry of the ‘Act earlier’ concept in the market
  • Improvement in diagnostic techniques
  • Growing demand for fixed-dose combinations


Chronic Obstructive Pulmonary Disease Market Barriers


  • Late recognition of COPD
  • High cost of treatment
  • Challenges in existing therapies
  • Patient-related barriers
  • Drug failure
  • Availability of generics


Chronic Obstructive Pulmonary Disease Emerging Therapies


The emerging drugs in the Chronic Obstructive Pulmonary Disease market are

  • Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb)
  • Dupixent (Dupilumab)
  • Tyvaso (Inhaled treprostinil solution)
  • Ensifentrine (RPL554)
  • Fasenra (Benralizumab)
  • CHF6001 (Tanimilast)
  • Nucala (Mepolizumab)
  • MV130 (Bactek)
  • MEDI3506
  • SelK2
  • Epeleuton (DS102)
  • NOV-14 (CSJ117)
  • Zofin
  • NTHi Mcat investigational vaccine (GSK3277511A)
  • Icenticaftor (QBW251)
  • Kalydeco (Ivacaftor/VX-770)
  • PUL-042 Inhalation Solution
  • Benlysta (Belimumab)
  • Azithromycin
  • Tezepelumab
  • Acumapimod (BCT-197)
  • BIO-11006 Inhalation Solution


Chronic Obstructive Pulmonary Disease Key Players 


The key players working in the Chronic Obstructive Pulmonary Disease market are


  • Sanofi
  • Regeneron Pharmaceuticals
  • United Therapeutics
  • Verona Pharma PLC
  • AstraZeneca
  • Chiesi Farmaceutici S.p.A
  • GlaxoSmithKline
  • Inmunotek
  • Tetherex Pharmaceuticals Corporation
  • Afimmune
  • Novartis Pharmaceuticals
  • Organicell Regenerative Medicine
  • Vertex Pharmaceuticals Incorporated
  • Pulmotect Inc.
  • Genentech
  • Amgen
  • Mereo BioPharma
  • Biomarck Pharmaceuticals